[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 3, 1977

Medical News

JAMA. 1977;238(14):1441-1456. doi:10.1001/jama.1977.03280150011001

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Mass screening for open spina bifida needs careful consideration  Recent British experience with the use of α-fetoprotein (α-fp) levels in amniotic fluid and maternal blood to detect neural tube defects (NTDs) has confronted Americans with some difficult decisions. British studies have established that elevated α-fp levels in amniotic fluid are diagnostic for anencephaly and open spina bifida and that measurement of α-fp levels in the serum of pregnant women can also detect a high proportion of these fetal abnormalities. (Closed spina bifida is only sometimes associated with elevated α-fp levels.) However, the decision of whether to use amniocentesis in all high-risk pregnancies, to institute maternal serum screening for NTDs, or to do neither depends only partly on the sensitivity of the tests. Important nonmedical factors include financial costs and benefits of such programs, practical difficulties in implementing them, psychological benefits to parents, and the public's cooperation with the programs.